According to a new market research study of “Netherton Syndrome Market to 2027 –  Analysis and Forecast by Therapy and Region,” the global Netherton syndrome market is expected to reach US$ 74.31 million by 2027 from US$ 19.57 million in 2019; it is estimated to grow at a CAGR of 20.3% from 2020 to 2027. The report highlights trends prevailing in the global Netherton syndrome market, and the factors driving or hindering the market growth.

Netherton syndrome is a rare disorder characterized by trichorrhexis invaginata, atopic diathesis, and ichthyosiform erythroderma. The trichorrhexis invaginata indicates short and brittle hair, atopic diathesis represents susceptibility to allergy problems while ichthyosiform erythroderma encompasses red, inflamed, scaly skin. Netherton syndrome is hereditary as it is an autosomal recessive trait. The disease is majorly caused due to mutations associated with SPINK5 gene. In some cases, although there is no family history of the disease, the syndrome is revealed even when two healthy parents that carry the mutated recessive gene have a child, which receives both copies of the recessive gene.

The final report will add the analysis of the Impact of Covid-19 in this report NETHERTON SYNDROME MARKET.

Adapting to the recent novel COVID-19 pandemic, the impact of the COVID-19 pandemic on the global NETHERTON SYNDROME MARKET is included in the present report. The influence of the novel coronavirus pandemic on the growth of the LASER MATERIALS  Market is analyzed and depicted in the report.

Some of the companies competing in the NETHERTON SYNDROME Market are 


  1. Lifemax Laboratories, Inc.
  2. Azitra, Inc.
  3. Sixera Pharma Ab
  4. Dermelix Biotherapeutics
  5. Matrisys Bioscience
  6. Quoin Pharmaceuticals Ltd.
  7. Krystal Biotech, Inc


Get a Sample Copy : https://www.theinsightpartners.com/sample/TIPRE00005617/

Based on therapy, the Netherton syndrome market is segmented into keratolytic agents, oral and topical steroids and retinoids, topical calcineurin inhibitors, biological therapies, and radiation therapies. In 2019, the keratolytic agents segment accounted for the largest share of the global market. The market growth of this segment is attributed to the increasing product launches and robust existing product pipeline. In addition, strategic activities by implemented by drug manufacturers such as collaborations, partnerships, and expansions to expedite the process of drug introduction are also projected to drive growth of the market. However, the Netherton syndrome market for the biological therapy segment is estimated to growth at the faster CAGR during the forecast period.

 

ABOUT US:

The Insight Partners is a one stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

 

Contact US:

If you have any queries about this report or would like further information, please contact us:


North America:          +1 646 491 9876
Asia-Pacific:               +91 20 6727 8686
Email:                         sales@theinsightpartners.com